News

"Changes at InVivo Therapeutics after I left the company in August of 2013 have permanently limited wide market adoption of my first generation of NeuroScaffolds. PixarBio’s Novel NR-SCI

In the Octave Induction 1 and Octave Induction 2 studies, tofacitinib reduced symptoms of moderate to severe UC and induced remission of the disease. In one study, 18.5%

The FDA has set a target action date under the Prescription Drug User Fee Act ("PDUFA") of July 14, 2016. SequestOxTM is an immediate-release Oxycodone Hydrochloride containing sequestered

Financial terms of the transaction were not disclosed. "This transaction gives us the opportunity to economically benefit from the antibiotic assets in our infectious disease portfolio and to

Osteogenesis imperfecta, also known as brittle bone disease or Lobstein syndrome, affects how the body produces collagen, a protein that helps strengthen bones. OI is often lethal before

This decision overturns FDA’s previous position reached at a lower level and clears the path toward approval for Travivo, an antidepressant with a unique mechanism of action and

Under a phase 1b/2 study, Kite’s investigational anti-CD19 Chimeric Antigen Receptor (CAR) T cell product, KTE-C19, will be evaluated with Genentech’s investigational anti-PDL1 antibody atezolizumab. The study, which

The primary endpoint of the study demonstrated that the Advair Diskus-combination (FSC) twice-daily showed non-inferiority compared to corresponding doses of fluticasone propionate (FP) twice-daily on the risk of

Kovaltry is an unmodified full-length recombinant factor VIII product, which is designed to reduce bleeding in patients with hemophilia A when administered prophylactically two or three times a